Abstract
The aim of this study was to evaluate the prognostic value of clinician interpretation of positron emission tomography/computed tomography (PET/CT) reports at mid-therapy, interim PET (I-PET) and after the end of first-line therapy (E-PET) in patients with diffuse large B-cell lymphoma (DLBCL). Four hundred and thirty patients were enrolled in this study comprising a total of 617 PET reports. Each report was evaluated by three expert hematologists randomly selected from a panel of nine. Reports were labeled positive or negative if all three interpreters agreed. All others were considered indeterminate. Indeterminate reports accounted for 59% of I-PET and 49% of E-PET reports. Two-year overall survival (OS) for patients with a positive, indeterminate and negative I-PET was 58%, 87% and 89% (p
| Originalsprog | Engelsk |
|---|---|
| Tidsskrift | Leukemia and Lymphoma |
| Vol/bind | 55 |
| Udgave nummer | 7 |
| Sider (fra-til) | 1563-69 |
| ISSN | 1042-8194 |
| DOI | |
| Status | Udgivet - 2014 |
Fingeraftryk
Dyk ned i forskningsemnerne om 'Prognostic impact of clinician-based interpretation of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography reports obtained in patients with newly diagnosed diffuse large B-cell lymphoma'. Sammen danner de et unikt fingeraftryk.Citationsformater
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS